ClinicalTrials.gg
RecruitingNCT07859020EP-AI ASSISTUpdated Oct 30, 2026

AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)

An observational study in Tachycardia, Paroxysmal Supraventricular Tachycardia and Wolff-Parkinson-White Syndrome, sponsored by Inha University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionTachycardia, VentricularRegistry: TachycardiaReclassifiedWhy we changed it
Registry
Tachycardia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tachycardia, Ventricular
Why
  1. The study's listed conditions name Tachycardia, Ventricular, a narrower term within Tachycardia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Inha University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 30, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Ages
19 Years and older
Sex
All
01

Study summary

This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.

02

Conditions studied

  • Tachycardia
  • Paroxysmal Supraventricular Tachycardia
  • Wolff-Parkinson-White Syndrome
  • Premature Ventricular Contractions
  • Ventricular Tachycardia

Browse trials for

Keywords

  • Artificial Intelligence
  • Electrocardiogram
  • Transformer
  • Catheter Ablation
  • Multicenter Study
03

In context

Tachycardia, Ventricular Reclassified

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 167 across 147 observational studies indexed under Tachycardia, Ventricular.

Browse Tachycardia, Ventricular studies →

Lead sponsor

Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.

Compared within Tachycardia, Ventricular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tachycardia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Retrospective cohort of patients aged 19 years or older with PSVT, WPW syndrome, PVC, or VT who underwent electrophysiological study and catheter ablation at participating institutions between January 2005 and December 2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 years or older
  • Diagnosis of one of the following arrhythmias: paroxysmal supraventricular tachycardia (PSVT), Wolff-Parkinson-White (WPW) syndrome, premature ventricular contractions (PVC), or ventricular tachycardia (VT)
  • Underwent an electrophysiological study (EPS) and catheter ablation
  • Available 12-lead (ECG) records that can be extracted as text (XML) files

Exclusion criteria

Exclusion Criteria:

  • Inadequate data quality, as judged by the investigator
  • Missing medical records required for the study, as judged by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiovascular Disease and Tachycardia Cohort

    Patients aged 19 years or older diagnosed with tachycardias (including PSVT, WPW syndrome, PVC, or VT) who underwent an electrophysiological study (EPS) and radiofrequency catheter ablation (RFCA), with extractable 12-lead ECG text data\[cite: 1\].

    Diagnostic Test: AI-based ECG Diagnostic and Localization Algorithm

Interventions

  • Diagnostic testAI-based ECG Diagnostic and Localization Algorithm

    Application of a deep learning-based 12-lead electrocardiogram (ECG) algorithm to analyze raw text data for the differential diagnosis and localization of tachycardias, including PSVT, WPW syndrome, PVC, and VT\[cite: 1\].

06

What researchers measure

Primary outcomes

  1. Area Under the ROC Curve (AUC) of AI-ECG Models for Differentiating Tachycardia Mechanisms Confirmed by Electrophysiological Study

    Diagnostic performance of Transformer-based deep learning models applied to 12-lead ECG raw data for differentiating tachycardia mechanisms, including atrioventricular nodal reentrant tachycardia (AVNRT) versus atrioventricular reentrant tachycardia (AVRT). The reference standard is the diagnosis confirmed by electrophysiological study and catheter ablation. Performance is summarized as AUC with 95% confidence interval (range 0-1; higher values indicate better discrimination).

    Time frame: Baseline

Secondary outcomes

  1. Area Under the ROC Curve (AUC) of AI-ECG Models for Localizing Arrhythmia Origin Sites (Accessory Pathway, PVC, and VT) Confirmed by Successful Catheter Ablation

    Performance of AI-ECG models in classifying the anatomical site of the arrhythmia substrate from the pre-ablation 12-lead ECG, including (1) accessory pathway location in Wolff-Parkinson-White syndrome, (2) the origin of premature ventricular contractions, and (3) the origin of ventricular tachycardia. The reference standard is the site identified by electrophysiological mapping and confirmed by successful catheter ablation. For each classification task, performance is reported as AUC with 95% confidence interval (range 0-1; higher values indicate better classification).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers due to institutional data privacy policies and ethical regulations concerning retrospective clinical records and encrypted electrocardiogram data.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
Dec 1, 2023
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 3 added, 1 removed; 2 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedPatients aged 19 years or older diagnosed with tachycardias (including PSVT, WPW syndrome, PVC, or VT) who have undergone an electrophysiological study (EPS) and radiofrequency catheter ablation (RFCA).
  • AddedAge 19 years or older
  • AddedDiagnosis of one of the following arrhythmias: paroxysmal supraventricular tachycardia (PSVT), Wolff-Parkinson-White (WPW) syndrome, premature ventricular contractions (PVC), or ventricular tachycardia (VT)
  • AddedUnderwent an electrophysiological study (EPS) and catheter ablation
  • EditedPatients withAvailable 12-lead electrocardiogram (ECG) records extractablethat can be extracted as text (XML) files.
Exclusion criteria
  • Removed- Patients deemed inappropriate as study subjects by the investigator's judgment based on data quality or missing medical records.
  • AddedInadequate ECG data quality, as judged by the investigator
  • AddedMissing medical records required for the study, as judged by the investigator
Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Diagnostic Performance (AUC-ROC) of AI-ECG ModelsNow Area Under the ROC Curve (AUC) of AI-ECG Models for Differentiating Tachycardia Mechanisms Confirmed by Electrophysiological StudyTime frame: Baseline
Oct 30, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Localization Accuracy of Tachycardia Origin SitesNow Area Under the ROC Curve (AUC) of AI-ECG Models for Localizing Arrhythmia Origin Sites (Accessory Pathway, PVC, and VT) Confirmed by Successful Catheter AblationTime frame: Baseline
Oct 30, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 30, 2026
    Eligibility 1 inclusion criterion edited, 3 added, 1 removed; 2 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients aged 19 years or older diagnosed with tachycardias (including PSVT, WPW syndrome, PVC, or VT) who have undergone an electrophysiological study (EPS) and radiofrequency catheter ablation (RFCA).
    • AddedAge 19 years or older
    • AddedDiagnosis of one of the following arrhythmias: paroxysmal supraventricular tachycardia (PSVT), Wolff-Parkinson-White (WPW) syndrome, premature ventricular contractions (PVC), or ventricular tachycardia (VT)
    • AddedUnderwent an electrophysiological study (EPS) and catheter ablation
    • EditedPatients withAvailable 12-lead electrocardiogram (ECG) records extractablethat can be extracted as text (XML) files.
    Exclusion criteria
    • Removed- Patients deemed inappropriate as study subjects by the investigator's judgment based on data quality or missing medical records.
    • AddedInadequate ECG data quality, as judged by the investigator
    • AddedMissing medical records required for the study, as judged by the investigator
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Diagnostic Performance (AUC-ROC) of AI-ECG ModelsNow Area Under the ROC Curve (AUC) of AI-ECG Models for Differentiating Tachycardia Mechanisms Confirmed by Electrophysiological StudyTime frame: Baseline
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Localization Accuracy of Tachycardia Origin SitesNow Area Under the ROC Curve (AUC) of AI-ECG Models for Localizing Arrhythmia Origin Sites (Accessory Pathway, PVC, and VT) Confirmed by Successful Catheter AblationTime frame: Baseline
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859020
Lead sponsor
Inha University Hospital
Responsible party
Yong-Soo Baek (Professor, Inha University Hospital) — Principal investigator
First posted
Oct 5, 2026
Start date
Dec 1, 2023
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Yongsoo Baek, MD, PhD
Contact
existsoo@inha.ac.kr
+82-32-890-2200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion